Daisuke Yabe

List of Publications by Year
in descending order

176 papers	7,759 citations	87888 38 h-index	53230 85 g-index
185 all docs	185 docs citations	185 times ranked	8792 citing authors

#	Article	IF	Citations
1	Hypoglycemic coma in an elderly adult switched from twice-daily vildagliptin to once-daily glimepiride to improve drug adherence. Diabetology International, 2022, 13, 295-299.	1.4	1
2	Efficacy and safety of oral semaglutide by baseline age in <scp>J</scp>apanese patients with type 2 diabetes: A subgroup analysis of the <scp>PIONEER</scp> 9 and 10 <scp>J</scp>apan trials. Diabetes, Obesity and Metabolism, 2022, 24, 321-326.	4.4	5
3	Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. Expert Opinion on Drug Safety, 2022, 21, 425-434.	2.4	2
4	Healthcare resource utilization in patients treated with empagliflozin in East Asia. Journal of Diabetes Investigation, 2022, 13, 810-821.	2.4	6
5	Glucokinase-maturity onset diabetes mellitus in the young suggested by factory-calibrated glucose monitoring data: a case report. Endocrine Journal, 2022, 69, 473-477.	1.6	1
6	First Japanese Family With PDX1-MODY (MODY4): A Novel PDX1 Frameshift Mutation, Clinical Characteristics, and Implications. Journal of the Endocrine Society, 2022, 6, bvab159.	0.2	11
7	Efficacy and safety of oral semaglutide in Japanese patients with typeâ€‰2 diabetes: A subgroup analysis by baseline variables in the PIONEERâ€‰9 and PIONEERâ€‰10 trials. Journal of Diabetes Investigation, 2022, 13, 975-985.	2.4	10
8	High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides. Nutrients, 2022, 14, 975.	4.1	5
9	Efficacy and safety of onceâ€weekly semaglutide in Japanese individuals with typeâ€‰2 diabetes by baseline age and body mass index. Journal of Diabetes Investigation, 2022, , .	2.4	7
10	Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan. Journal of Diabetes Investigation, 2022, 13, 429-431.	2.4	2
11	Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study. Expert Opinion on Drug Safety, 2022, , .	2.4	0
12	Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetology International, 2022, 13, 693-697.	1.4	3
13	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINAÂ® trial. Diabetology International, 2021, 12, 87-100.	1.4	12
14	Effect of hypertriglyceridemia in dyslipidemiaâ€induced impaired glucose tolerance and sex differences in dietary features associated with hypertriglyceridemia among the Japanese population: The Gifu Diabetes Study. Journal of Diabetes Investigation, 2021, 12, 771-780.	2.4	1
15	Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00183.	2.4	23
16	Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report. BMC Endocrine Disorders, 2021, 21, 13.	2.2	2
17	Effects of ChREBP deficiency on adrenal lipogenesis and steroidogenesis. Journal of Endocrinology, 2021, 248, 317-324.	2.6	6
18	Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids. American Journal of Physiology - Renal Physiology, 2021, 320, G617-G626.	3.4	3

#	Article	IF	Citations
19	A novel RFX6 heterozygous mutation (p.R652X) in maturityâ€onset diabetes mellitus: A case report. Journal of Diabetes Investigation, 2021, 12, 1914-1918.	2.4	5
20	Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodiumâ€“glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open, 2021, 11, e045844.	1.9	18
21	Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3778-e3780.	3.6	3
22	iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A postâ€hoc analysis of the LixiLan JPâ€L trial. Journal of Diabetes Investigation, 2021, 12, 1992-2001.	2.4	2
23	127-LB: Effectiveness and Safety of Empagliflozin in Routine Care in Europe and East Asia: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study. Diabetes, 2021, 70, 127-LB.	0.6	2
24	Effects of glucagonâ€like peptideâ€1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. Journal of Diabetes Investigation, 2021, 12, 2162-2171.	2.4	12
25	Voxelâ€based specific regional analysis system for Alzheimerâ€™s disease utility as a screening tool for unrecognized cognitive dysfunction of elderly patients in diabetes outpatient clinics: Multicenter retrospective exploratory study. Journal of Diabetes Investigation, 2021, , .	2.4	3
26	Effects of physicianâ€™s diabetes selfâ€management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a selfâ€monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, openâ€label, prospective randomized clinical trial. Journal of Diabetes Investigation, 2021, , .	2.4	0
27	Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in <scp>J</scp>apan: Post hoc analysis of the <scp>LixiLan JPâ€O2</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2795-2803.	4.4	2
28	Ceritinibâ€associated hyperglycemia in the Japanese Adverse Drug Event Report Database. Journal of Diabetes Investigation, 2020, 11, 726-730.	2.4	5
29	Sodiumâ€“glucose cotransporterÂ2 inhibitor and sarcopenia in a lean elderly adult with typeÂ2 diabetes: A case report. Journal of Diabetes Investigation, 2020, 11, 745-747.	2.4	24
30	Factory-calibrated continuous glucose monitoring and capillary blood glucose monitoring in a case with insulinoma: usefulness and possible pitfall under chronic hyperinsulinemic hypoglycemia. Endocrine Journal, 2020, 67, 361-366.	1.6	2
31	Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan. BMJ Open Diabetes Research and Care, 2020, 8, e001361.	2.8	6
32	Generation and Characterization of a Novel Mouse Model That Allows Spatiotemporal Quantification of Pancreatic Î²-Cell Proliferation. Diabetes, 2020, 69, 2340-2351.	0.6	10
33	Benefits of the fixedâ€ratio combination of insulin glargine 100â€‰units/<scp>mL</scp> and lixisenatide (<scp>iGlarLixi</scp>) in Japanese people with type 2 diabetes: A subgroup and timeâ€toâ€control analysis of the <scp>LixiLan JP</scp> phase 3 trials. Diabetes, Obesity and Metabolism, 2020, 22, 35-47.	4.4	7
34	The Smart Life Stay (SLS) program: effects of a lifestyle intervention program in combination with health tourism and health guidance for type 2 diabetes. Nutrition and Diabetes, 2020, 10, 33.	3.2	3
35	A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes. Nutrients, 2020, 12, 2502.	4.1	13
36	ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue. Frontiers in Endocrinology, 2020, 11, 587189.	3.5	64

#	Article	IF	Citations
37	Single-Cell Transcriptome Analysis Dissects the Replicating Process of Pancreatic Beta Cells in Partial Pancreatectomy Model. IScience, 2020, 23, 101774.	4.1	15
38	Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 392-406.	11.4	91
39	Alcoholâ€induced impaired insulin secretion in a Japanese population: 5â€year follow up in the Gifu Diabetes Study. Journal of Diabetes Investigation, 2020, 11, 1207-1214.	2.4	5
40	Cardioprotective effects of GLPâ€1(28â€36a): A degraded metabolite or GLPâ€1â€™s better half?. Journal of Diabetes Investigation, 2020, 11, 1422-1425.	2.4	2
41	Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINAÂ® Trial. Diabetes Therapy, 2020, 11, 1721-1734.	2.5	3
42	A case of MODY5-like manifestations without mutations or deletions in coding and minimal promoter regions of the HNF1B gene. Endocrine Journal, 2020, 67, 981-988.	1.6	0
43	The Role of Metagenomics in Precision Nutrition. Nutrients, 2020, 12, 1668.	4.1	6
44	SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes. Internal Medicine, 2020, 59, 1535-1539.	0.7	4
45	Utility of microcatheter in adrenal venous sampling for primary aldosteronism. British Journal of Radiology, 2020, 93, 20190636.	2.2	10
46	Diabetes and COVID-19: IDF perspective in the Western Pacific region. Diabetes Research and Clinical Practice, 2020, 166, 108278.	2.8	7
47	Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors. Cancer Research, 2020, 80, 3620-3630.	0.9	11
48	The Asian Association for the Study of Diabetes: The first 10Âyears and the next 10Âyears. Journal of Diabetes Investigation, 2020, 11, 1079-1084.	2.4	1
49	Association of glucagonâ€like peptideâ€1 receptorâ€targeted imaging probe with inÂvivo glucagonâ€like peptideâ€1 receptor agonist glucoseâ€lowering effects. Journal of Diabetes Investigation, 2020, 11, 1448-1456.	2.4	9
50	Tumorâ€like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretinâ€induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat. Journal of Diabetes Investigation, 2020, 11, 1434-1447.	2.4	3
51	Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: A Single-center Experience of Five Consecutive Cases. Internal Medicine, 2020, 59, 2397-2403.	0.7	5
52	1818-P: High-Sucrose Diet Causes Increased Hepatic Histone Acetylation Due to Increased Bacterial Acetate Production and Reduced Lipogenesis in ChREPB-Deficient Mice. Diabetes, 2020, 69, .	0.6	0
53	1660-P: Exome Sequencing in a Family with Multiple Cases of Early-Onset Diabetes Reveals a Candidate Causative Mutation in the PTF1A Gene. Diabetes, 2020, 69, 1660-P.	0.6	1
54	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase Iâ€“<scp>III</scp> clinical trials. Journal of Diabetes Investigation, 2019, 10, 418-428.	2.4	27

#	Article	IF	Citations
55	The journey to understanding incretin systems: Theory, practice and more theory. Journal of Diabetes Investigation, 2019, 10, 1171-1173.	2.4	5
56	Dietary instructions focusing on meal-sequence and nutritional balance for prediabetes subjects: An exploratory, cluster-randomized, prospective, open-label, clinical trial. Journal of Diabetes and Its Complications, 2019, 33, 107450.	2.3	9
57	Response of a superconductor NbSe₂ flake to magnetic field detected with small tunnel junctions. Journal of Physics: Conference Series, 2019, 1293, 012016.	0.4	0
58	GPR40 activation initiates store-operated Ca2+ entry and potentiates insulin secretion via the IP3R1/STIM1/Orai1 pathway in pancreatic Î²-cells. Scientific Reports, 2019, 9, 15562.	3.3	27
59	Low-carbohydrate diet by staple change attenuates postprandial GIP and CPR levels in type 2 diabetes patients. Journal of Diabetes and Its Complications, 2019, 33, 107415.	2.3	6
60	Dietary recommendations for typeÂ2 diabetes patients: Lessons from recent clinical and basic research in Asia. Journal of Diabetes Investigation, 2019, 10, 1405-1407.	2.4	6
61	Bullous pemphigoid with dipeptidyl peptidaseâ€4 inhibitors: Clinical features and pathophysiology. Journal of Diabetes Investigation, 2019, 10, 1168-1170.	2.4	15
62	Sphingosine kinase 1â€“interacting protein is a dual regulator of insulin and incretin secretion. FASEB Journal, 2019, 33, 6239-6253.	0.5	6
63	A rare case of autoimmune polyglandular syndrome with SjÃ¶grenâ€™s syndrome and primary hypoparathyroidism. BMJ Case Reports, 2019, 12, e228634.	0.5	2
64	Twincretin as a potential therapeutic for the management of typeÂ2 diabetes with obesity. Journal of Diabetes Investigation, 2019, 10, 902-905.	2.4	18
65	2150-P: Single Cell RNA-Sequencing Dissects Proliferation of Pancreatic Beta Cells. Diabetes, 2019, 68, 2150-P.	0.6	0
66	41-OR: Store-Operated Ca2+ Entry Activated by STIM1 Plays an Essential Role in GPR40-Mediated GIIS Potentiation. Diabetes, 2019, 68, 41-OR.	0.6	0
67	1018-P: Comparison of Short- and Long-Acting Glucagon-Like Peptide-1 Receptor Agonist Effects on Postprandial Glucose and Lipid Excursion via Gastric Emptying. Diabetes, 2019, 68, 1018-P.	0.6	0
68	1019-P: Glucagon-Like Peptide-1 Receptor Agonists Predominantly Reduce Body Fat Mass in Patients with Type 2 Diabetes. Diabetes, 2019, 68, 1019-P.	0.6	1
69	110-OR: Generation of a Novel Mouse Model to Study ÃŸ-Cell Proliferation. Diabetes, 2019, 68, 110-OR.	0.6	0
70	786-P: Serum Dehydroepiandrosterone Sulfate Concentration and Animal Protein Intakes Are Important Factors for Skeletal Muscle Mass in Japanese Patients with Type 2 Diabetes. Diabetes, 2019, 68, 786-P.	0.6	0
71	771-P: Protein Intake at Breakfast Contributes to Maintenance of Skeletal Muscle Mass in Japanese Elderly Patients with Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	0
72	Japanese Clinical Practice Guideline for Diabetes 2016. Journal of Diabetes Investigation, 2018, 9, 657-697.	2.4	158

#	Article	IF	Citations
73	Relationship between deterioration of glycated hemoglobinâ€lowering effects in dipeptidyl peptidaseâ€4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes. Journal of Diabetes Investigation, 2018, 9, 1153-1158.	2.4	14
74	Mental distress and healthâ€related quality of life among type 1 and type 2 diabetes patients using selfâ€monitoring of blood glucose: A crossâ€sectional questionnaire study in Japan. Journal of Diabetes Investigation, 2018, 9, 1203-1211.	2.4	9
75	Sodiumâ€glucose cotransporterâ€2 inhibitor luseogliflozin added to glucagonâ€like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52â€week, openâ€label, singleâ€arm study. Journal of Diabetes Investigation, 2018, 9, 332-340.	2.4	38
76	Bullous pemphigoid associated with dipeptidyl peptidaseâ€4 inhibitors: A report of five cases. Journal of Diabetes Investigation, 2018, 9, 445-447.	2.4	37
77	Incretin concept revised: The origin of the insulinotropic function of glucagonâ€like peptideâ€1 â€“ the gut, the islets or both?. Journal of Diabetes Investigation, 2018, 9, 21-24.	2.4	20
78	Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining Î²â€cell function and the achievement of the glycated hemoglobin target 1 year after initiation. Journal of Diabetes Investigation, 2018, 9, 822-830.	2.4	20
79	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp>apanese people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 378-388.	4.4	82
80	Cover Image, Volume 20, Issue 2. Diabetes, Obesity and Metabolism, 2018, 20, i-i.	4.4	0
81	Case 23-2018: A Man with Episodes of Confusion and Hypoglycemia. New England Journal of Medicine, 2018, 379, 1881-1882.	27.0	4
82	Reply to the comment of Wilbrink etÂal. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining Î²â€cell function and the achievement of the HbA1c target 1Âyear after initiation. Journal of Diabetes Investigation, 2018, 9, 981-983.	2.4	2
83	A novel ultrasonography measurement of internal carotid artery stenosis: comparison with the North American Symptomatic Carotid Endarterectomy Trial angiographic method. Neurosonology, 2018, 31, 1-6.	0.0	0
84	Japanese Clinical Practice Guideline for Diabetes 2016. Diabetology International, 2018, 9, 1-45.	1.4	215
85	Hypoglycemia Unawareness in Insulinoma Revealed with Flash Glucose Monitoring Systems. Internal Medicine, 2018, 57, 3407-3412.	0.7	10
86	Betaâ€cell replacement strategies for diabetes. Journal of Diabetes Investigation, 2018, 9, 457-463.	2.4	30
87	Effects of Dietary Instructions Including Meal-Sequence for Prediabetes Subjectsâ€”Comparison with Conventional Approach. Diabetes, 2018, 67, 53-LB.	0.6	1
88	Deterioration of HbA1c-Lowering Effects in Dipeptidyl-Peptidase Inhibitor and Dietary Habits in Japanese Type 2 Diabetesâ€”Comparison with That of Metformin. Diabetes, 2018, 67, .	0.6	0
89	Safety and Tolerability of Empagliflozin in East Asian Patients with Type 2 Diabetesâ€”Pooled Analysis of Phase I-III Clinical Trials. Diabetes, 2018, 67, 1150-P.	0.6	0
90	Factors Responsible for Progression of Microalbuminuria in Japanese Patients with Type 2 Diabetes-Retrospective Analysis. Diabetes, 2018, 67, 540-P.	0.6	0

#	Article	IF	Citations
91	Efficacy and safety of sitagliptin as compared with glimepiride in <scp>J</scp>apanese patients with type 2 diabetes mellitus agedâ€‰â‰¥â€‰60â€‰years (<scp>STARTâ€J</scp> trial). Diabetes, Obesity and Metabolism, 2017, 19, 1188-1192.	4.4	18
92	Sodiumâ€glucose coâ€transporterâ€2 inhibitor use and dietary carbohydrate intake in <scp>J</scp>apanese individuals with type 2 diabetes: <scp>A</scp> randomized, openâ€label, 3â€arm parallel comparative, exploratory study. Diabetes, Obesity and Metabolism, 2017, 19, 739-743.	4.4	57
93	Effects of <scp>DPP</scp>â€4 inhibitor linagliptin and <scp>GLP</scp>â€1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, openâ€label, 2â€arm parallel comparative, exploratory trial. Diabetes, Obesity and Metabolism, 2017, 19, 442-447.	4.4	23
94	Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety, 2017, 16, 1211-1218.	2.4	18
95	Electrical properties of carbon-nanotube-network transistors in air after gamma irradiation. Physica E: Low-Dimensional Systems and Nanostructures, 2017, 86, 297-302.	2.7	5
96	Cardiovascular safety trials of incretin-based drugs: What do they mean?. Journal of Diabetes Investigation, 2017, 8, 272-276.	2.4	7
97	Insulinoma with a History of Epilepsy: Still a Possible Misleading Factor in the Early Diagnosis of Insulinoma. Internal Medicine, 2017, 56, 3199-3204.	0.7	10
98	Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance. Journal of Diabetes Research, 2016, 2016, 1-8.	2.3	15
99	Effects of SGLT2 inhibitor luseogliflozin under different dietary formula in type 2 diabetes: A randomized, controlled exploratory trial. Diabetes Research and Clinical Practice, 2016, 120, S52.	2.8	0
100	Use of the Japanese health insurance claims database to assess safety of SGLT2 inhibitors in the management of diabetes. Diabetes Research and Clinical Practice, 2016, 120, S52.	2.8	1
101	Comparison of short-and long-acting glucagon-like peptide 1 receptor agonists on postprandial glucose excursion, insulin and glucagon secretions and gastric emptying. Diabetes Research and Clinical Practice, 2016, 120, S124-S125.	2.8	0
102	Long-term glucose lowering effects of sitagliptin monotherapy and dietary contents in Japanese individuals with type 2 diabetes. Diabetes Research and Clinical Practice, 2016, 120, S128.	2.8	0
103	Efficacy and safety comparison of sitagliptin and glimepiride in elderly Japanese patients with type 2 diabetes: START-J. Diabetes Research and Clinical Practice, 2016, 120, S130-S131.	2.8	0
104	Clinical implication of diabetes education program declaring a goal in life for patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 120, S165.	2.8	0
105	Original diabetes education program including individual self-care plan â€œMy Goals Sheetâ€•ameliorates long-term glycemic control in patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 120, S177.	2.8	0
106	Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin. Diabetologia, 2016, 59, 1533-1541.	6.3	15
107	Incretinâ€based drugs for type 2 diabetes: Focus on East Asian perspectives. Journal of Diabetes Investigation, 2016, 7, 102-109.	2.4	144
108	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse Î²-cell function in the GetGoal-M and GetGoal-S trials. Journal of Diabetes and Its Complications, 2016, 30, 1385-1392.	2.3	15

#	Article	IF	Citations
109	Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. Diabetologia, 2016, 59, 453-461.	6.3	69
110	Type 2 diabetes via Î²-cell dysfunction in east Asian people. Lancet Diabetes and Endocrinology,the, 2016, 4, 2-3.	11.4	52
111	Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 249-264.	2.4	6
112	Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan. Journal of Diabetes and Its Complications, 2015, 29, 1304-1309.	2.3	13
113	Efficacy and safety of lixisenatide in Japanese patients with typeÂ2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of <scp>G</scp>et<scp>G</scp>oalâ€<scp>S</scp>. Journal of Diabetes Investigation, 2015, 6, 201-209.	2.4	11
114	A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the disease. Endocrine Journal, 2015, 62, 1025-1030.	1.6	5
115	Î² Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians. Current Diabetes Reports, 2015, 15, 602.	4.2	231
116	Total Ionizing Dose Effects in Carbon Nanotube Network Transistors. , 2015, , .		1
117	Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining Î²-cell function and achievement of HbA1c target one year after initiation. Journal of Diabetes and Its Complications, 2015, 29, 1203-1210.	2.3	17
118	Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. Journal of Diabetes and Its Complications, 2015, 29, 413-421.	2.3	53
119	A case of hypoglycemia due to illegitimate sexual enhancement medication. Diabetes Research and Clinical Practice, 2015, 108, e8-e10.	2.8	12
120	Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. Expert Opinion on Drug Safety, 2015, 14, 795-800.	2.4	73
121	Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. Current Medical Research and Opinion, 2015, 31, 1267-1270.	1.9	13
122	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Diabetology International, 2015, 6, 151-187.	1.4	65
123	Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal InsulinÂ±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study. Hormone and Metabolic Research, 2015, 47, 895-900.	1.5	12
124	Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP â€4 inhibitors with other oral antidiabetic drugs. Diabetes, Obesity and Metabolism, 2015, 17, 430-434.	4.4	22
125	Circulating TNF Receptor 2 is Closely Associated with the Kidney Function in Non-Diabetic Japanese Subjects. Journal of Atherosclerosis and Thrombosis, 2014, 21, 730-738.	2.0	9
126	Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2014, 9, 547-559.	2.4	1

#	Article	IF	Citations
127	Factors influencing the durability of the glucoseâ€lowering effect of sitagliptin combined with a sulfonylurea. Journal of Diabetes Investigation, 2014, 5, 445-448.	2.4	21
128	PO046 COMPARISON OF FISH OR MEAT INTAKE BEFORE AND AFTER RICE ON POSTPRANDIAL GLUCOSE EXCURSIONS AND INCRETIN SECRETION IN TYPE 2 DIABETES: MEAL-SEQUENCE AS A NOVEL TARGET IN DIETARY THERAPY FOR DIABETES. Diabetes Research and Clinical Practice, 2014, 106, S68-S69.	2.8	0
129	Dipeptidyl peptidaseâ€4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?. Journal of Diabetes Investigation, 2014, 5, 475-477.	2.4	45
130	Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2014, 9, 659-670.	2.4	14
131	Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2014, 15, 851-863.	1.8	11
132	Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2014, 105, 302-312.	2.8	82
133	Relationship and factors responsible for regulating fasting and postâ€challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus. Journal of Diabetes Investigation, 2014, 5, 663-670.	2.4	2
134	Improvement of Fasting Plasma Glucose Level After Ingesting Moderate Amount of Dietary Fiber in Japanese Men With Mild Hyperglycemia and Visceral Fat Obesity. Journal of Dietary Supplements, 2013, 10, 129-141.	2.6	13
135	Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: Implications for glucagon-like peptide-1 secretion from pancreatic Î± cells in vivo. Diabetes Research and Clinical Practice, 2013, 102, e1-e4.	2.8	9
136	Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2013, 99, 145-150.	2.8	13
137	Incretin actions beyond the pancreas: lessons from knockout mice. Current Opinion in Pharmacology, 2013, 13, 946-953.	3.5	42
138	Glucoseâ€dependent insulinotropic polypeptide and glucagonâ€like peptideâ€1: Incretin actions beyond the pancreas. Journal of Diabetes Investigation, 2013, 4, 108-130.	2.4	207
139	Retrospective analysis of safety and efficacy of insulinâ€toâ€liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced Î²â€cell function. Journal of Diabetes Investigation, 2013, 4, 585-594.	2.4	25
140	Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese. Journal of Diabetes Investigation, 2012, 3, 377-383.	2.4	10
141	Dipeptidylâ€peptidaseâ€ƒIV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. Journal of Diabetes Investigation, 2012, 3, 498-502.	2.4	18
142	Predicting efficacy of dipeptidyl peptidaseâ€4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. Journal of Diabetes Investigation, 2012, 3, 464-467.	2.4	31
143	Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation, 2012, 3, 70-79.	2.4	59
144	Smoking and adipose tissue inflammation suppress leptin expression in Japanese obese males: Potential mechanism of resistance to weight loss among Japanese obese smokers. Tobacco Induced Diseases, 2012, 10, 3.	0.6	17

#	Article	IF	Citations
145	Dipeptidyl peptidaseâ€4 inhibitors and prevention of bone fractures: Effects beyond glyemic control. Journal of Diabetes Investigation, 2012, 3, 347-348.	2.4	8
146	Glucagonâ€like peptideâ€1 secretion by direct stimulation of L cells with luminal sugar vs nonâ€nutritive sweetener. Journal of Diabetes Investigation, 2012, 3, 156-163.	2.4	18
147	Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin. Diabetes Therapy, 2012, 3, 14.	2.5	24
148	Circadian rhythms and diabetes. Journal of Diabetes Investigation, 2011, 2, 176-177.	2.4	16
149	Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and Î² cell preservation. Progress in Biophysics and Molecular Biology, 2011, 107, 248-256.	2.9	150
150	Smoking, white blood cell counts, and TNF system activity in Japanese male subjects with normal glucose tolerance. Tobacco Induced Diseases, 2011, 9, 12.	0.6	10
151	Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. Clinical Medicine Insights: Endocrinology and Diabetes, 2011, 4, CMED.S5976.	1.9	16
152	Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes. Endocrine Journal, 2010, 57, 119-126.	1.6	68
153	The Role of Family Nutritional Support in Japanese Patients with Type 2 Diabetes Mellitus. Internal Medicine, 2010, 49, 983-989.	0.7	17
154	Little enhancement of mealâ€induced glucagonâ€like peptideâ€ƒ1 secretion in Japanese: Comparison of typeâ€ƒ2 diabetes patients and healthy controls. Journal of Diabetes Investigation, 2010, 1, 56-59.	2.4	80
155	GIP and GLPâ€1, the two incretin hormones: Similarities and differences. Journal of Diabetes Investigation, 2010, 1, 8-23.	2.4	467
156	Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19029-19034.	7.1	146
157	A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestion. Diabetes Research and Clinical Practice, 2008, 82, e1-e4.	2.8	5
158	Msx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signaling. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1610-1615.	7.1	50
159	Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1616-1620.	7.1	72
160	Multiple roles of Notch signaling in cochlear development. Developmental Biology, 2007, 307, 165-178.	2.0	94
161	Rbpâ€j regulates expansion of pancreatic epithelial cells and their differentiation into exocrine cells during mouse development. Developmental Dynamics, 2007, 236, 2779-2791.	1.8	32
162	Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARP. Genesis, 2007, 45, 300-306.	1.6	37

#	Article	IF	Citations
163	Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. Cell Metabolism, 2006, 3, 59-65.	16.2	103
164	Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas. Journal of Molecular Medicine, 2006, 84, 37-45.	3.9	157
165	Liver-specific mRNA for Insig-2 down-regulated by insulin: Implications for fatty acid synthesis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3155-3160.	7.1	260
166	Insig-dependent Ubiquitination and Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-CoA Reductase Stimulated by Sterols and Geranylgeraniol. Journal of Biological Chemistry, 2003, 278, 52479-52490.	3.4	254
167	Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11694-11699.	7.1	132
168	Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12753-12758.	7.1	449
169	Three mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterols. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 16672-16677.	7.1	83
170	Crucial Step in Cholesterol Homeostasis. Cell, 2002, 110, 489-500.	28.9	861
171	Regulated Step in Cholesterol Feedback Localized to Budding of SCAP from ER Membranes. Cell, 2000, 102, 315-323.	28.9	307
172	DANCE, a Novel Secreted RGD Protein Expressed in Developing, Atherosclerotic, and Balloon-injured Arteries. Journal of Biological Chemistry, 1999, 274, 22476-22483.	3.4	170
173	Human Calumenin Gene (CALU): cDNA Isolation and Chromosomal Mapping to 7q32. Genomics, 1998, 49, 331-333.	2.9	32
174	Molecular Cloning, Characterization, and Chromosomal Localization of FKBP23, a Novel FK506-Binding Protein with Ca2+-Binding Ability. Genomics, 1998, 54, 89-98.	2.9	39
175	Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant. Science, 1998, 279, 389-393.	12.6	674
176	Calumenin, a Ca2+-binding Protein Retained in the Endoplasmic Reticulum with a Novel Carboxyl-terminal Sequence, HDEF. Journal of Biological Chemistry, 1997, 272, 18232-18239.	3.4	96